Panacea biotec Limited has received positive developments in an ongoing tax litigation matter involving its wholly owned subsidiary. The company announced on March 11, 2026, that Panacea Biotec Pharma Limited (PBPL) received a favorable order from Maharashtra tax authorities, resulting in a significant reduction of the tax demand.

Tax Demand Reduction Details

The Deputy Commissioner of State Tax, Maharashtra, issued an order dated March 10, 2026, addressing PBPL's appeal filed in May 2025. The appeal was against a demand order originally issued by the Adjudicating Officer in Financial Year 2024-25.

Background of Tax Litigation

The original tax demand pertained to alleged excess or ineligible Input Tax Credit and other tax liabilities. The demand included tax, interest, and penalty components totaling ₹1.58 crore. PBPL had filed an appeal in May 2025 challenging this demand order.

Company's Position and Next Steps

Despite the favorable reduction, Panacea Biotec maintains its position that the revised demand of ₹0.81 crore is not maintainable. Based on internal assessment, the company has decided to pursue further legal remedies:

• PBPL is taking necessary steps to file an appeal with the appellate authority
• The company is challenging the revised order through proper legal channels
• All required documentation and procedures are being followed

Impact Assessment

Panacea Biotec has stated that it does not envisage any relevant impact on the financial, operational, or other activities of the company or PBPL from this matter. The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance

The announcement was made in compliance with SEBI regulations, with detailed information provided to both NSE and BSE. The company has fulfilled all disclosure requirements under the applicable regulations and master circulars issued by SEBI.

Panacea Biotec has secured a major legal victory in its prolonged tax litigation battle, with the Income Tax Appellate Tribunal (ITAT) New Delhi delivering a comprehensive favorable ruling that eliminates a substantial tax demand of ₹329.49 Crore. The tribunal's decision addresses appeals spanning Assessment Years 2005-06 to 2012-13, marking the resolution of a complex tax dispute that has persisted for over a decade.

ITAT Ruling Details

The Income Tax Appellate Tribunal's comprehensive order addressed multiple appeals from both the tax authorities and the Company. The tribunal's decision encompassed three critical rulings that collectively favored Panacea Biotec across all contested assessment years, eliminating all expense disallowances that had been imposed by the tax authorities.

The DCIT appeals were filed against orders from the Commissioner of Income Tax (Appeals), New Delhi, arising from distinct assessment orders passed under sections 148/143(3) of the Income Tax Act. The Company's successful appeals were against orders from CIT Appeals, stemming from assessment orders under sections 153A/143(3) of the Act.

Financial Impact and Tribunal Order Confirmation

The tribunal's ruling delivers substantial financial relief to Panacea Biotec by eliminating the entire tax demand that had been raised by the Assessing Officer. The Company has confirmed that the tribunal order specifically deletes all disallowances of expenses across the contested assessment years, providing comprehensive relief from the disputed tax liability totaling 3.29 billion rupees.

The ruling effectively nullifies substantial contingent tax liabilities and potential penalty exposures that had been associated with these assessment years. This comprehensive relief removes a significant financial overhang that had persisted across multiple fiscal periods, potentially improving the Company's financial position and reducing regulatory uncertainties.

Regulatory Compliance and Disclosure

Panacea Biotec disclosed this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company received the ITAT order and promptly informed the stock exchanges about this material development.

The disclosure confirms that the litigation did not involve key management personnel, promoters, or ultimate persons in control of the Company. Additionally, the resolution did not involve any settlement arrangements, compensation payments, or penalties, as the tribunal ruled entirely in favor of the Company across all contested matters.

Assessment Years and Legal Framework

The disputed assessments covered eight consecutive years from 2005-06 to 2012-13, representing a comprehensive challenge to the Company's tax positions across nearly a decade of operations. The original assessment orders were passed under various sections of the Income Tax Act, including sections 148, 143(3), and 153A, indicating the scope and complexity of the tax authorities' examination.

The successful resolution of these appeals demonstrates Panacea Biotec's ability to defend its tax positions effectively through the appellate process. The tribunal's decision to quash the assessment orders entirely, rather than merely reducing the demands, provides the Company with complete relief from the contested tax liabilities and associated compliance burdens.